Effectiveness of high-dose versus standard-dose influenza vaccines against severe respiratory and secondary cardiovascular outcomes in adults aged ≥80 years
Publication date: November 2026 Source: Clinical Microbiology and Infection, Volume 32, Issue 11 Author(s): Laura Díaz-Estévez, Mario Rivera-Izquierdo, Nicolás Francisco Fernández-Martínez, Daniel Ocaña-Rodríguez, David Moreno-Pérez, Nicola Lorusso
Effectiveness of high-dose versus standard-dose influenza vaccines against severe respiratory and secondary cardiovascular outcomes in adults aged ≥80 years. // Clinical Microbiology and Infection. – URL: https://www.sciencedirect.com/science/article/pii/S1198743X26003307?dgcid=rss_sd_all
Effectiveness of high-dose versus standard-dose influenza vaccines against severe respiratory and secondary cardiovascular outcomes in adults aged ≥80 years. Clinical Microbiology and Infection. https://www.sciencedirect.com/science/article/pii/S1198743X26003307?dgcid=rss_sd_all
“Effectiveness of high-dose versus standard-dose influenza vaccines against severe respiratory and secondary cardiovascular outcomes in adults aged ≥80 years.” Clinical Microbiology and Infection.
@article{article41123,
title = {Effectiveness of high-dose versus standard-dose influenza vaccines against severe respiratory and secondary cardiovascular outcomes in adults aged ≥80 years},
journal = {Clinical Microbiology and Infection},
url = {https://www.sciencedirect.com/science/article/pii/S1198743X26003307?dgcid=rss_sd_all}
}
ABSTRACT Background Aspergillus fumigatus can cause life‐threatening infections, primarily treated with azole antifungals. Azole‐resistant A. fumigatus (ARAF) is a major clinical concern. Environmental resistance development is an...
ABSTRACT Background The lipid‐dependent yeast genus Malassezia is composed of skin commensals that can become pathogenic. This genus can cause bloodstream infection in low‐weight preterm neonates and immunocompromised adults. However,...